<DOC>
	<DOCNO>NCT01074554</DOCNO>
	<brief_summary>Growing research independent laboratory provide association mycobacteria sarcoidosis . More recent immunologic molecular study demonstrate immune response mycobacteria virulence factor . The purpose study assess administration anti-mycobacterial drug therapy aid resolution cutaneous sarcoidosis lesion .</brief_summary>
	<brief_title>Trial Antimycobacterial Therapy Sarcoidosis</brief_title>
	<detailed_description>Independent molecular immunologic investigation strengthen association mycobacterial antigen sarcoidosis pathogenesis . Molecular analysis sarcoidosis granuloma reveals presence Mycobacterium tuberculosis complex ( MTB ) DNA proteins significantly absent granulomatous control . Mycobacterial DNA detect cutaneous sarcoidosis lesion , addition systemic immune response mycobacterial antigen . Due association sarcoidosis mycobacterial antigen , postulate broad spectrum antimycobacterial therapy could lead restoration T cell function clinical improvement chronic cutaneous sarcoidosis lesion . We investigate safety efficacy Concomitant Levofloxacin , Ethambutol , Azithromycin , Rifampin ( CLEAR ) therapy among chronic cutaneous sarcoidosis subject , change lesion diameter baseline completion 8 week therapy primary endpoint ; assess decrease granuloma burden , granuloma evident upon histologic examination . Change modify Sarcoidosis Activity Severity Index ( SASI ) secondary endpoint .</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>1 . Patients sarcoidosis define ATS/ERS/WASOG statement sarcoidosis define clinical presentation consistent sarcoidosis , biopsy find granuloma , alternative cause granuloma , tuberculosis 2 . Patients must chronic cutaneous skin lesion without take chronic therapy ( corticosteroid , methotrexate ( max 10mg/week ) , azathioprine , hydroxychloroquine , cyclophosphamide , minocycline , doxycycline chloroquine ) , dose alter 2 month prior start study . 3 . Subject diagnosis cutaneous sarcoidosis great 6 month Sarcoidosis Activity Severity Index assessment score least 4 . Diagnosis make either : Skin lesion characteristic sarcoidosis biopsy show granulomas evidence mycobacteria , fungus , malignancy . A biopsy show granuloma , patient characteristic skin lesion history clinical feature suggest sarcoidosis ( previous biopsy reveal noncaseating granuloma , bilateral hilar adenopathy , erythema nodosum , uveitis , raise ACE level , BAL lymphocytosis ( CD4 : CD8 &gt; 3.5 ) , panda/lambda sign gallium scan ) Accepted clinical variant include , necessarily limit follow : lupus pernio nodular subcutaneous annular angiolupoid plaque papular lichenoid psoriasiform For purpose study `` moderate severe cutaneous sarcoidosis '' define presence sarcoidal skin lesion follow feature : At least 5 easily visible facial lesion , Disease involve &gt; 3 % BSA , Disease confer functional impairment ( e.g . nasal visual field obstruction ) , Disease confer significant symptom itch and/or pain . 4 . If female , subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) , use one follow method birth control duration study 90 day study completion : condom , sponge , foam , jelly , diaphragm , intrauterine device contraceptive ( oral parenteral ) three month prior study drug administration vasectomize sole partner Females childbearing potential must negative serum pregnancy test screen visit . 1 . No consent/inability obtain consent . 2 . Age le 18 year age . 3 . Inability obtain biopsy draw blood . 4 . CPK , ALT AST &gt; 5 time upper limit normal ( ULN ) 5 . Pregnancy breast feed . 6 . Current use medication metabolize rifampin ( See Appendix ) . 7 . Allergy macrolides , quinolones rifamycins . 8 . Visual Impairment define differentiate color . 9 . Family personal history long QT syndrome . 10 . Patients receive another interventional investigational drug within 30 day prior dose 11 . Use investigational medication within past 28 day prior study enrollment . 12 . Subject hospitalized infection receive IV antibiotic within previous 2 month prior baseline . 13 . Subject history tuberculosis anytime close contact person active tuberculosis within previous 6 month , persistent active infection require hospitalization treatment IV antibiotic , IV antiretrovirals , IV antifungal within 30 day baseline , OR oral antibiotic , antiviral , antifungal purpose treat infection , within 14 day baseline . 14 . Evidence active skin disease skin infection screen may interfere evaluation sarcoidosis . 15 . Subject active infection require systemic antibiotic time screen 16 . Subject history listeriosis , treat untreated tuberculosis , exposure individual tuberculosis . 17 . Subject variant sarcoidosis amenable study evaluation , absence chronic indurate lesion , : Acute , `` benign '' sarcoid associate erythema nodosum Acute iritis Ichthyosiform sarcoidosis Hypo hyperpigmented macular sarcoidosis Ulcerative sarcoidosis Erythroderma Alopecia 18 . Patients otherwise unsuitable participation opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>sarcoidosis</keyword>
	<keyword>mycobacteria</keyword>
	<keyword>cutaneous lesion</keyword>
</DOC>